BioSpace News Archive

Basilea Pharmaceutica Ltd announced that on an unaudited preliminary basis it expects to have achieved an operating profit of approximately CHF 18 million for the financial year 2022 and expects to report a net profit.

Hyloris Pharmaceuticals SA announces that its partner AFT Pharmaceuticals has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals for Maxigesic® IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous infusion, in 9 European markets.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, the healthcare division of Yas Holding LLC, announced that the Saudi Food & Drug Authority has approved the manufacturing and distribution of AVT02, a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases.

Axion BioSystems, a leader in live-cell analysis tools, announced the full integration of imaging innovator CytoSMART Technologies into the Axion BioSystems brand.

Gandeeva Therapeutics, Inc., a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy and machine learning, announced the appointment of Brenda G. Cooperstone, MD, as an independent member of its Board of Directors.

ATUM, a global specialist and industry leader in bioengineering solutions, announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.

MannKind Corporation announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven B. Binder, will participate in the Lytham Partners Investor Select Conference taking place virtually on Tuesday January 31, 2023.

SaNOtize Research and Development Corp., a Canadian anti-infective-focused therapeutics company, announced the formation of its inaugural scientific advisory board, comprised of internationally renowned scientific and clinical leaders from Canada, the United States, and Europe.

Zomedica Corp. announced today that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023.

KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.